ESMO Asia 2018

Roche at ESMO Asia 2018

ESMO Asia 2018 will keep oncology professionals in the Asia-Paciﬁc region up to date about the most recent breakthroughs in cancer research, innovative treatments and ongoing investigations.

Daily reports from ASH 2018 by Springer Healthcare

Daily report from the first three days of ASH 2018. Read more

Symposium

60 mins

22 Oct 2018

ESMO Asia Symposium Continuing progress in the treatment of GU cancers: first-line immunotherapy options and combination strategies

Symposium

13 mins

22 Oct 2018

ESMO filming with Professor Zhou 2018: Primary results of ALESIA - a randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC

Posters

PDF

Nov 24, 2018 | Oncology

PDF

ESMO Asia 2018

ESMO-Asia Poster 2018 IMbrave150: A Randomised Phase III Study of Atezolizumab + Bevacizumab vs Sorafenib in Locally Advanced or Metastatic Hepatocellular Carcinoma

Nov 24, 2018 | Oncology
Oncology
IMbrave150 is a randomized Phase III study that investigates the effects of atezolizumab (anti–PD-L1) + bevacizumab (anti–VEGF) combination therapy vs sorafenib in first-line hepatocellular carcinoma (HCC). It will enroll patients with locally advanced or metastatic and/or unresectable HCC. This Trial in Progress poster presents study design, eligibility criteria, endpoints and enrollment sites of the study.

Presentations

PDF

Nov 23, 2018 | Oncology ESMO Asia 2018 Oncology

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

PDF

Nov 23, 2018 | Lung Cancer ESMO Asia 2018 Lung Cancer

ESMO-Asia Oral IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations

PDF

Nov 24, 2018 | Lung Cancer ESMO Asia 2018 Lung Cancer

ESMO Asia oral IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)